Download Sample
Add to CartOpioid Induced Constipation (OIC) Market
By Type;
Branded and GenericsBy Drug Class;
Aminosalicylates, Digestive Enzymes, Proton Pump Inhibitors, Laxatives, Anti-Emetics, H2 Antagonists, Anti-Diarrheal, Biologics & Biosimilars and OthersBy Route of Administration;
Oral, Injectable and OthersBy Application;
Crohn's Disease, Ulcerative Colitis, GERD, IBS and OthersBy Distribution Channel;
Hospital Pharmacies, Retail Pharmacies and Online PharmaciesBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)Opioid Induced Constipation Market Overview
Opioid Induced Constipation Market (USD Million)
Opioid Induced Constipation Market was valued at USD 15,127.65 million in the year 2024. The size of this market is expected to increase to USD 105,071.52 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 31.9%.
Opioid Induced Constipation (OIC) Market
*Market size in USD million
CAGR 31.9 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 31.9 % |
| Market Size (2024) | USD 15,127.65 Million |
| Market Size (2031) | USD 105,071.52 Million |
| Market Concentration | Low |
| Report Pages | 300 |
Major Players
- Purdue Pharma
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
- Salix Pharmaceuticals
- Shionogi & Co., Ltd.
- Mallinckrodt Pharmaceuticals
- Progenics Pharmaceuticals, Inc.
- Shire (now part of Takeda)
- Daiichi Sankyo Company, Limited
- Pfizer Inc.
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Opioid Induced Constipation (OIC) Market
Fragmented - Highly competitive market without dominant players
The opioid induced constipation (OIC) market is witnessing strong growth with the increasing use of opioid-based medications for pain relief. Studies show that nearly 40–50% of patients on opioids experience constipation, creating significant demand for targeted therapies. The recognition of OIC as a medical condition is fueling innovation and treatment adoption, aimed at improving patient well-being and compliance.
Prevalence of OIC
As opioids remain widely prescribed for both chronic and acute pain, OIC has emerged as a common complication. Data reveals that approximately 45% of long-term opioid users face moderate to severe constipation that disrupts daily activities. This prevalence underscores the need for effective therapeutic solutions integrated into opioid care plans.
Innovation in Therapies
Therapeutic advances such as peripherally acting mu-opioid receptor antagonists (PAMORAs) are transforming the treatment landscape. Research highlights that over 55% of patients benefit from these drugs, experiencing relief without loss of analgesic effect. These innovations are boosting adherence to opioid regimens and enhancing patient satisfaction.
Awareness and Proactive Management
Growing patient and physician awareness is leading to earlier recognition and intervention for OIC. Surveys indicate that 60% of patients now openly communicate constipation symptoms during consultations, up from less than 40% in earlier years. This improved dialogue supports proactive management strategies and wider adoption of OIC therapies.
Opioid Induced Constipation Market Recent Developments
- In November 2023, a study published in MDPI explored the use of opioid antagonists in line with dysbiosis and opioid-induced constipation in the present and future.
- In May 2022, a study published in Medical Science explored the effectiveness of itopride in the management of opioid-induced constipation among palliative care patients.
Opioid Induced Constipation Market Segment Analysis
In this report, the opioid induced constipation market has been segmented by Drug Class, Prescription Type, End User and Geography.
Opioid Induced Constipation Market, Segmentation by Drug Class
The Opioid Induced Constipation Market has been segmented by Drug Class into Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators and Others.
Mu-opioid Receptor Antagonists
Mu-opioid receptor antagonists dominate the opioid induced constipation market with about 62% of total share, offering targeted relief by blocking opioid receptors in the gastrointestinal tract without affecting pain control. Increased clinical adoption and strong efficacy profiles are driving growth in this segment.
Chloride Channel-2 Activators
Chloride channel-2 activators hold nearly 25% of the market share, working by enhancing intestinal fluid secretion to ease bowel movement. Rising preference for non-opioid based therapies and supportive clinical guidelines are boosting demand in this category.
Others
The “Others” segment, representing around 13% of the market, includes laxatives, stool softeners, and emerging combination therapies. Growing awareness of multi-mechanism treatment approaches is gradually expanding adoption rates.
Opioid Induced Constipation Market, Segmentation by Prescription Type
The Opioid Induced Constipation Market has been segmented by Prescription Type into Over The Counter and Prescription.
Over The Counter
Over the counter products hold about 47% of the opioid induced constipation market, offering accessible self-care solutions such as laxatives and stool softeners. Growing consumer preference for readily available treatments and increasing awareness of opioid-related side effects are fueling demand in this segment.
Prescription
Prescription medications account for approximately 53% of the market share, including targeted therapies like mu-opioid receptor antagonists and chloride channel activators. Rising physician recommendations and proven clinical efficacy are key drivers of growth in this category.
Opioid Induced Constipation Market, Segmentation by End User
The Opioid Induced Constipation Market has been segmented by End User into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.
Hospital Pharmacies
Hospital pharmacies account for about 41% of the opioid induced constipation market, dispensing specialized prescription therapies directly to inpatients and post-surgical patients. The segment benefits from physician oversight and immediate access to advanced treatment options.
Retail Pharmacies
Retail pharmacies hold nearly 46% of the market share, offering both prescription and over-the-counter products for opioid-induced constipation. Their wide accessibility and trusted role in patient counseling support continued growth in this category.
Online Pharmacies
Online pharmacies represent around 13% of the market, providing home delivery services and convenient access to a range of constipation treatments. Increasing digital healthcare adoption and competitive pricing are fueling expansion in this segment.
Opioid Induced Constipation Market, Segmentation by Geography
In this report, The Opioid Induced Constipation Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Regions and Countries Analyzed in this Report
Opioid Induced Constipation Market Share (%), by Geographical Region
North America
North America leads the opioid induced constipation market with about 39% of global share, driven by high opioid prescription rates, advanced healthcare infrastructure, and widespread availability of specialized treatment options. Strong regulatory support and awareness programs further enhance market growth.
Europe
Europe holds approximately 27% of the market share, supported by robust healthcare systems, rising pain management treatments, and increased patient education on opioid-related side effects. The adoption of innovative drug formulations is steadily increasing.
Asia Pacific
Asia Pacific accounts for around 22% of the market and is the fastest-growing region due to expanding healthcare access, growing opioid usage in pain therapy, and rising awareness of gastrointestinal side effects. Investment in pharmaceutical R&D is boosting growth.
Middle East & Africa
The Middle East & Africa represent about 6% of the global market, with growth supported by healthcare modernization and greater access to pain management treatments. Gradual adoption of targeted constipation therapies is being observed.
Latin America
Latin America holds roughly 6% of the opioid induced constipation market, driven by improving healthcare infrastructure, increased drug availability, and rising awareness campaigns promoting early treatment.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Opioid Induced Constipation Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Increasing Prescription of Opioid Medications
- Growing Awareness of Opioid-Related Side Effects
-
Regulatory Emphasis on Safer Treatment Options- Regulatory bodies globally are placing a heightened emphasis on the development and approval of safer treatment options for opioid-induced constipation (OIC). As the adverse effects of opioid medications, including constipation, garner increased attention, regulatory agencies are working to ensure that patients have access to effective therapies that mitigate these side effects while maintaining pain management efficacy. This regulatory focus has led to more stringent requirements for the evaluation of OIC treatments during clinical trials, emphasizing safety endpoints alongside measures of efficacy. Additionally, regulatory agencies are advocating for post-marketing surveillance programs to monitor the real-world safety and effectiveness of approved OIC therapies, enabling timely detection and management of any emerging risks.
The regulatory emphasis on safer treatment options for OIC is driving pharmaceutical companies to innovate and develop novel therapeutic approaches. Recognizing the need for medications that specifically target constipation without compromising pain relief, drug developers are investing in the research and development of peripherally acting mu-opioid receptor antagonists (PAMORAs) and other targeted therapies. These agents aim to block the effects of opioids on the gastrointestinal tract while preserving their analgesic effects, offering patients a more favorable risk-benefit profile compared to traditional laxatives or opioid antagonists.
Regulatory agencies are working collaboratively with healthcare providers and patient advocacy groups to raise awareness about OIC and promote the adoption of safer treatment options in clinical practice. By providing guidance and educational resources, regulatory bodies empower clinicians to make informed decisions regarding OIC management, ultimately improving patient outcomes and quality of life. This collaborative effort underscores the importance of regulatory oversight in driving advancements in OIC treatment and ensuring that patients receive safe and effective care in the context of opioid therapy.
Restraints:
- Limited Efficacy of Current Treatment Options
- Concerns about Abuse Potential of Opioid Antagonists
-
Cost Constraints in Healthcare Budgets- Cost constraints in healthcare budgets present a significant challenge in addressing opioid-induced constipation (OIC) within the global market. As healthcare systems grapple with rising expenditures and limited resources, the allocation of funds for OIC management may be constrained, leading to potential barriers in access to effective treatments. The high cost of certain pharmacological agents used to alleviate OIC, such as peripherally acting mu-opioid receptor antagonists (PAMORAs), can strain healthcare budgets, particularly in regions with limited reimbursement coverage or reliance on public healthcare funding. Additionally, the need for ongoing management and monitoring of OIC adds to the overall healthcare expenditure, further exacerbating budgetary constraints.
Cost considerations may influence treatment decisions and access to care for patients experiencing OIC. Healthcare providers may opt for less expensive or generic alternatives, which may not always offer optimal efficacy or tolerability compared to newer, more expensive therapies. Additionally, cost-conscious prescribing practices and formulary restrictions imposed by payers can limit patient access to innovative OIC treatments, potentially compromising treatment outcomes and patient satisfaction. The challenge lies in balancing the imperative to manage healthcare costs with the need to provide comprehensive and effective care for individuals living with OIC.
Cost constraints also present opportunities for stakeholders within the OIC market to innovate and optimize resource utilization. Pharmaceutical companies may explore strategies to reduce the cost of developing and manufacturing OIC therapies, such as streamlining production processes or leveraging economies of scale. Similarly, healthcare providers can implement cost-effective approaches to OIC management, including preventive measures, non-pharmacological interventions, and collaborative care models that maximize the use of available resources while ensuring quality patient care. By addressing cost constraints creatively and collaboratively, stakeholders can work towards improving access to effective OIC treatments within the constraints of healthcare budgets.
Opportunities:
- Development of Novel Pharmacological Agents
- Expansion of Non-Pharmacological Treatment Approaches
-
Collaboration for Comprehensive Patient Care- Collaboration among stakeholders is paramount for achieving comprehensive patient care in the global opioid-induced constipation (OIC) market. This collaboration involves healthcare providers, pharmaceutical companies, regulatory agencies, patient advocacy groups, and other relevant parties working together to address the multifaceted challenges associated with OIC. By fostering partnerships and sharing expertise, stakeholders can develop holistic approaches to OIC management that prioritize patient well-being and treatment outcomes. This collaborative effort ensures that patients receive integrated care that considers both the management of pain and the mitigation of opioid-induced side effects like constipation.
Healthcare providers play a central role in facilitating collaboration for comprehensive patient care in the OIC market. They coordinate with specialists, such as gastroenterologists and pain management experts, to tailor treatment plans that address the unique needs of patients experiencing OIC. Additionally, healthcare providers engage in interdisciplinary teamwork, involving nurses, pharmacists, and allied health professionals, to deliver personalized care and support to individuals affected by OIC. By fostering communication and collaboration within healthcare teams, providers can optimize treatment outcomes and enhance patient satisfaction.
Collaboration in the OIC market extends beyond clinical settings to encompass research, advocacy, and policy development. Pharmaceutical companies collaborate with academic institutions and research organizations to advance the development of novel therapies for OIC and conduct clinical trials to evaluate their safety and efficacy. Regulatory agencies collaborate with stakeholders to establish guidelines and standards for the safe and effective management of OIC, ensuring that patients have access to high-quality care. Additionally, patient advocacy groups play a vital role in raising awareness about OIC, advocating for improved access to treatment options, and empowering patients to actively participate in their care journey. Through collaborative efforts across multiple domains, stakeholders can drive positive change and improve outcomes for patients affected by OIC.
Opioid Induced Constipation (OIC) Market Competitive Landscape Analysis
Opioid Induced Constipation (OIC) Market is characterized by strong competition among pharmaceutical companies focusing on specialized gastrointestinal treatments. Leading players emphasize strategies such as product diversification, targeted partnerships, and clinical development programs to reinforce market positioning. Increasing emphasis on advanced formulations and expanded therapeutic coverage continues to drive growth across major segments.
Market Structure and ConcentrationThe market shows a balanced mix of established pharmaceutical leaders and emerging biotechnology firms. While a significant percentage of revenue share is dominated by few players, increasing collaboration and licensing agreements enhance competitive depth. This concentration drives aggressive strategies in regulatory filings, ensuring faster expansion across therapeutic portfolios.
Brand and Channel StrategiesCompanies employ multi-layered strategies to strengthen brand presence, including direct specialist outreach, digital engagement, and hospital network partnerships. Brand loyalty is reinforced by patient assistance initiatives and clinical support programs. Distribution channels are increasingly diversified, ensuring broader accessibility and stronger growth momentum across institutional and retail segments.
Innovation Drivers and Technological AdvancementsR&D pipelines emphasize innovation with novel peripherally acting mu-opioid receptor antagonists and improved drug delivery methods. Technological advancements in formulation enhance therapeutic outcomes, minimizing side effects and improving adherence rates. Continuous clinical trials and research partnerships significantly influence market competitiveness and foster sustainable growth.
Regional Momentum and ExpansionRegional markets exhibit varying degrees of adoption, with North America holding a substantial percentage share driven by early innovation adoption. Europe follows with strong reimbursement strategies, while Asia-Pacific demonstrates the fastest expansion through healthcare modernization and regional collaboration. Local partnerships and policy alignment remain key drivers of regional momentum.
Future OutlookThe future outlook highlights a shift toward precision-based therapies, enhanced regulatory approvals, and wider payer acceptance. Industry leaders are expected to prioritize merger activities and cross-sector partnerships to secure a competitive edge. With ongoing technological advancements and expanding patient awareness, the market is positioned for sustainable long-term growth.
Key players in Opioid Induced Constipation Market include:
- AstraZeneca plc
- Merck & Co., Inc.
- Shionogi & Co., Ltd.
- Bausch Health Companies Inc.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline plc
- Novartis AG
- Sanofi
- Bayer AG
- Ironwood Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Progenics Pharmaceuticals, Inc.
- Dr. Reddy's Laboratories Ltd.
- Cosmo Pharmaceuticals NV
- Cumberland Pharmaceuticals Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Opioid Induced Constipation (OIC) Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Prescription of Opioid Medications
- Growing Awareness of Opioid-Related Side Effects
- Regulatory Emphasis on Safer Treatment Options
- Restraints
- Limited Efficacy of Current Treatment Options
- Concerns about Abuse Potential of Opioid Antagonists
- Cost Constraints in Healthcare Budgets
- Opportunities
- Development of Novel Pharmacological Agents
- Expansion of Non-Pharmacological Treatment Approaches
- Collaboration for Comprehensive Patient Care
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Opioid Induced Constipation (OIC) Market, By Type, 2021-2031 (USD Million)
- Branded
- Generics
- Opioid Induced Constipation (OIC) Market, By Drug Class, 2021-2031 (USD Million)
- Aminosalicylates
- Digestive Enzymes
- Proton Pump Inhibitors
- Laxatives
- Anti-Emetics
- H2 Antagonists
- Anti-Diarrheal
- Biologics & Biosimilars
- Others
- Opioid Induced Constipation (OIC) Market, By Route of Administration, 2021-2031 (USD Million)
- Oral
- Injectable
- Others
- Opioid Induced Constipation (OIC) Market, By Application, 2021-2031 (USD Million)
- Crohn's Disease
- Ulcerative Colitis
- GERD
- IBS
- Others
- Opioid Induced Constipation (OIC) Market, By Distribution Channel, 2021-2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Opioid Induced Constipation (OIC) Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Opioid Induced Constipation (OIC) Market, By Type, 2021-2031 (USD Million)
- Competitive Landscape
- Company Profiles
- AstraZeneca plc
- Merck & Co., Inc.
- Shionogi & Co., Ltd.
- Bausch Health Companies Inc.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline plc
- Novartis AG
- Sanofi
- Bayer AG
- Ironwood Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Progenics Pharmaceuticals, Inc.
- Dr. Reddy's Laboratories Ltd.
- Cosmo Pharmaceuticals NV
- Cumberland Pharmaceuticals Inc.
- Company Profiles
- Analyst Views
- Future Outlook of the Market